Updates from the Infectious Diseases Society of America (IDSA)
Release date: October 28, 2019
Expiration date: October 30, 2022
BCOP credit must be claimed by: June 20, 2020
ACPE credit must be claimed by: December 20, 2022
HOPA is pleased to present the final webinar of a five-webinar series, which will review key findings from clinical and translational research, and data presented at national oncology meetings.
This BCOP webinar will review key abstracts and programming presented at the Infectious Diseases Society of America (IDSA) October 2019 meeting. It will discuss broad infectious complications and relevant infectious disease complications of the general population as well as infectious complications and management of the immune compromised host.
- Illustrate advances in the management of cytomegalovirus in the immune compromised host.
- Recognize recently presented abstracts in patients with C. difficile infection.
- Discover new findings in hematopoietic stem cell transplant patients.
- Review the use of fecal microbiota transplantation in patients with metastatic melanoma.
Anne M. McDonnell, PharmD BCOP
Dr. McDonnell is a Board-Certified Oncology Pharmacist, who received her Bachelor’s degree in pharmacy from the Massachusetts College of Pharmacy and Health Sciences, her Doctor of Pharmacy degree from the University of Arkansas for Medical Sciences and her Master of Business Administration from University of Louisiana Shreveport. She completed her pharmacy practice residency at New York-Presbyterian Hospital and her oncology pharmacy practice residency at the Medical University of South Carolina. Dr. McDonnell is a Past President of the Massachusetts Pharmacists Association and has also lectured and published on several topics. Dr. McDonnell worked as an oncology clinical specialist at Brigham and Women's Hospital in Boston, Massachusetts for more than twelve years before transitioning to ambulatory medication safety in February 2019 at Brigham and Women’s Hospital.
Heron Therapeutics (A) (H); Takeda (A) (H).
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-19-099-H04-P.
HOPA Member – $40
Nonmember – $70
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by December 20, 2022.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% or greater is achieved. Tests must be completed by June 20, 2020.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Planners and managers for the Hematology/Oncology Pharmacy Association do not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs – all faculty will indicate at the start of their presentations if they or will be referencing unlabeled/unapproved uses of drugs and devices.